Back to first-pass browser

First-pass extracted concept

Fas ligand

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

CD95L, FasL

Extracted Explainers

What the tool is doing

FasL is described as the ligand component of the Fas/CD95 pathway that can induce programmed cell death in Fas-sensitive target cells. In the review abstract, myeloma-cell FasL is presented as functionally active and implicated in immune escape.

Source 1DOIPubMed

Resources required

Its reported effect depends on Fas-sensitive target cells and the presence of the Fas/FasL signaling pathway. The abstract also references blocking and neutralizing antibodies as pathway probes.

Source 1DOIPubMed

What problem it solves

In the review's framing, FasL helps explain how immune privileged tissues and some tumor cells can eliminate or suppress attacking immune cells through apoptosis.

Source 1DOIPubMed

What it does not solve

The abstract does not present FasL itself as a therapeutic tool or a general solution for cancer treatment. It also notes that the molecular basis of the evasive mechanism differs from other tumor settings.

Source 1DOIPubMed

Alternatives

The supplied web summary mentions related apoptosis-ligand axes such as CD40 ligand and TRAIL/Apo2L as adjacent comparators, but the abstract itself does not develop them.

Source 1DOIPubMed

Evidence Snippets

The title and abstract center on the Fas (Apo-1/CD95) receptor/ligand (FasL) system and repeatedly discuss FasL expression and function in immune privileged tissues and myeloma cells.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1mechanistic interference summarysupports1998Source 1DOIPubMed

Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.

Claim 2mechanistic summarysupports1998Source 1DOIPubMed

In the myeloma model discussed in the review, neoplastic plasma cell lines and native malignant myeloma cells constitutively express FasL mRNA and protein, and the FasL is functionally active in killing Fas-sensitive target T cells in vitro.

Claim 3review scope summarysupports1998Source 1DOIPubMed

The review presents Fas/FasL signaling as a mechanism involved in immune privilege and also as a potential tumor immune escape strategy.